High grade gliomas: The role of dynamic contrast-enhanced susceptibility-weighted perfusion MRI and proton MR spectroscopic imaging in differentiating grade III from grade IV  by Zidan, Sayed et al.
The Egyptian Journal of Radiology and Nuclear Medicine 47 (2016) 1565–1573Contents lists available at ScienceDirect
The Egyptian Journal of Radiology and Nuclear Medicine
journal homepage: www.sciencedirect .com/locate /e j rnmOriginal ArticleHigh grade gliomas: The role of dynamic contrast-enhanced
susceptibility-weighted perfusion MRI and proton MR spectroscopic
imaging in differentiating grade III from grade IVhttp://dx.doi.org/10.1016/j.ejrnm.2016.10.002
0378-603X/ 2016 The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Peer review under responsibility of The Egyptian Society of Radiology and Nuclear
Medicine.
⇑ Corresponding author.Sayed Zidan a, Hazim I. Tantawy a,⇑, Mansour Abdelmagid Makia b
aDepartment of Radiodiagnosis, Faculty of Medicine, Zagazig University, Egypt
bDepartment of Neurosurgery, Faculty of Medicine, Zagazig University, Egypt
a r t i c l e i n f o a b s t r a c tArticle history:
Received 15 August 2016
Accepted 2 October 2016
Available online 7 October 2016
Keywords:
MRS
Dynamic contrast-enhanced perfusion MRI
Glioma grade III
Glioma grade IVBackground: Advanced MR imaging techniques provide physiologic information which complements the
conventional MRI findings.
Purpose: To evaluate the role of dynamic contrast-enhanced perfusion MRI and proton MR spectroscopy
(MRS) in differentiating grade-III from grade-IV glioma.
Results: 40 patients with preliminary diagnosis of glioma according to the conventional MRI study and
the WHO classification and grading of glioma underwent dynamic MRI study which revealed, 19 patients
(47.5%) are diagnosed as grade-III, and 21 cases (52.5%) are diagnosed as grade-IV. The tumor core relative
cerebral blood volume (rCBV) was highly significant (P = 0.000) in differentiating grade III from grade IV
with cutoff value of 6,sensitivity of 90.5%, specificity of 68.4%, PVP of 76% and NPV of 86.7%.
In proton MR spectroscopy, (CHo/Cr) ratio was significant in differentiating grade III from grade IV glioma
(P = 0.02), while CHo/NAA, NAA/Cr and MI/Cr ratios were not significant.
Conclusion: The rCBV estimation and the metabolite ratios separately or in combination increase the sen-
sitivity of grading of glioma rather than the conventional MRI.
 2016 The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).1. Introduction
Functional magnetic resonance imaging (MRI) techniques such
as diffusion, perfusion and MR spectroscopy can give important
in vivo physiological and metabolic information, complementing
conventional MRI findings regarding the precise detection and
grading of brain high grade glioma. Gliomas are the most common
primary neoplasms of the brain and have histologic findings that
vary from low to high grade [1]. The grading of glioma has signif-
icant clinical impact since high grade gliomas (HGGs) are usually
treated with adjuvant radio- or chemotherapy after resection
whereas low grade gliomas (LGGs) are not. Histopathologic assess-
ment is the current gold standard for tumor grading which has the
limitation of inherent sampling error associated with the limited
number of biopsy samples. The histopathological classification of
gliomas itself is a controversial subject [2]. The treatment protocoland length of survival rates are distinctly different between
anaplastic astrocytoma and glioblastoma multiform, and GBM
patients receive radiotherapy and chemotherapy with temozolo-
mide after the surgical removal of the tumor. In case of anaplastic
astrocytoma, the patients receive radiotherapy after surgical
removal of the tumor [3]. Both MR perfusion and spectroscopic
MR provide enough quantitative data to detect the malignancy
grade of cerebral glioma [4].2. Material and methods
This is a retrospective study in which a total of 40 patients (22
males and 18 females) aged from 23 years to 72 years with mean
age of 44 ± 4.6 years with pathologically proven after surgery
(resection or biopsy) high grade glioma in our institution in the
period from November 2013 to November 2015, for whom pre-
operative MRI (conventional), MRS and DCS MR imaging suitable
for evaluation were done (Figs. 1–4).
All the brain perfusion studies have been acquired on 1.5-T
superconducting MRI unit (Signa Excite HD; GE Healthcare,
Fig. 1. 29-year-old male patient with histologically confirmed grade-III anaplastic astrocytoma (A) Axial T1-weighted post Gd-DTPA image demonstrates lesion at left
anterior parasagittal parietal lobe with mild interrupted peripheral contrast enhancement with central cystic/necrotic region. (B) Axial FLAIR images demonstrate increase in
T2 signal within lesion with moderate surrounding edema. (C) Gradient-echo axial DSC MRI with rCBV & MTT color map demonstrates high perfusion rate and some
prolongation of MTT within tumor.(D) Signal intensity curve demonstrates a substantial initial signal drop indicating higher rCBV with slower return to baseline (rCBV = 6.2).
(E) Spectrum (TE = 35 ms) from tumoral region showing marked Cho elevation with respect to creatine (Cr) and N-acetylaspartate (NAA) which corresponds to areas of high
rCBV. Also there is increased perfusion around periphery of the lesion with decreased perfusion centrally within necrotic center that shows marked elevated lipid peak (F).
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software (Functool, GE Healthcare, Milwaukee, USA) workstation
with perfusion evaluation software.The perfusion was done as part of the routine contrast enhanced
brain examination for patients who were scheduled for surgery.
Our routine brain examination consists of pre-contrast conven-
Fig. 1 (continued)
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(Table 1).
2.1. MR spectroscopy
MRS was performed for all patients with PROPE-P [Proton spec-
troscopy examination with single, multiple, 2-D acquisition uses
PRESS sequence (proton resolved spectroscopy)]; single voxel
parameters are as follows: matrix size: 1  1, Locs per slab:1, slice
thickness:10–20, with TE of 35msec, and 2-D CSI (multi-voxel)
parameters are as follows: matrix size: 8  24, Locs per slab: 1,
slice thickness: 10–20 with TE of 144 ms.
2.2. Dynamic susceptibility contrast-enhanced perfusion MR (DSC-
MRI)
In our institution the DSC-MRI was performed using echo-
planer gradient-echo imaging, and the perfusion series protocol
is that after the precontrast portion of the brain examination is
done, be ready with injection, star the scan and inject the contrast
at the 8th measurement; the scan has 50 time points (measure-
ments) of 2 s each, resulting in total time just less than 2 min
using gadolinium-based contrast agent (1.0 mol/l of gadopentetate
dimeglumine (Magnevist; Berlex Laboratories, Wayne, NJ) was
injected intravenously at a rate of 4 ml/s using a power injector
and was followed by a 30-ml bolus of saline at the same injection
rate. After that, main series were sent to the workstation where we
do the post-processing of the images).
2.3. Post-processing
On Functool workstation, we open perfusion application. Areas
with necrosis, cysts, and large vessels were avoided. Tumor mar-
gins were defined on T2-weighted images, and for the contrast
enhancement T1-weighted images were checked and after selec-
tion of ROI for calculation; the relative cerebral blood volume
(rCBV), relative cerebral blood flow (rCBF) color images, mean tran-
sit time (MTT) and time-to-peak (TTP) maps are shown.
2.4. Interpretation
Each study was evaluated with two methods. First was a quan-
titative analysis based on color map images derived from the per-
fusion sequences, MR spectroscopy, and cutoff data reported in thethreshold of 1.75 for the relative cerebral blood volume (rCBV) [5],
1.5 for choline (CHo)/Creatine (Cr) ratio [6] and 1.5 for choline
(CHo)/N-acetylaspartate (NAA) ratio [7].
The regions of clinical interests: contrast enhanced regions, the
most restricted diffusivity regions and regions in contralateral
normal-appearing white matter. The volume of interest, varied
from 20 mm3 to 40 mm3 to avoid contamination from adjacent
non tumor areas. Blood volume, blood flow and mean transit time
maps were generated from perfusion sequences. MR spectroscopy
derived metabolites ratio (cHo/Cr, NAA/Cr, cHo/NAA, Lactate/Cr
and Lipid/Cr) were estimated. From diffusion weighted imaging
data, ADC maps were generated and values were assessed in each
area.
Second evaluation was qualitative analysis and based on con-
ventional MR imaging such as tumor contrast enhancement,
edema, mass effect, areas of necrosis and hemorrhage and
multifocality.
Data were statistically described in terms of mean ± standard
deviation (±SD), median and rang, or frequency (number of
cases) and percentages when appropriate. Comparison of numer-
ical variables between the study groups was done using Stu-
dent’s t-test for independent sample. Accuracy was represented
using the term sensitive, specific, +ve predictive value and ve
predictive value. Receiver operator characteristic (ROC) analysis
was used to determine the optimal cutoff value and overall accu-
racy. P value less than 0.05 was considered statistically signifi-
cant. All statistical calculations were done using computer
program (SPSS), Statistical package for social science (SPSS Inc.,
Chicago, IL, USA) version 15 for Microsoft workstation. All data
analysis, DCE-MRI and MR spectroscopy were correlated with
histopathology.3. Results
Of 40 patients examined in this study and according to the
WHO classification, 6 patients (15%) are diagnosed as grade-III
anaplastic astrocytomas (Fig. 1), 4 cases (10%) are diagnosed as
grade-III anaplastic oligodendroglioma (Fig. 3), 9 cases (22.5%)
are graded as grade-III anaplastic oligoastrocytoma, and 21 cases
(52.5%) are diagnosed as grade-IV glioblastoma (Figs. 2 and 4)
(Table 2).
The tumor core rCBV was highly significant (P = 0.000) in
differentiating G4 from G3 with cutoff value of 6 and a sensitivity
Fig. 2. 35-year-old male patient with histologically confirmed grade-IV glioblastoma. (A) Axial T1-weighted post Gd-DTPA image demonstrates a large lesion at right
temporoparietal lobe with marked heterogenous post G-d-DTPA enhancement. (B) Axial FLAIR images demonstrate increase in T2 signal intensity of lesion with marked
surrounding edema, shift of mid line to left side and effacement upon ventricular system. (C) Gradient-echo axial DSC MRI with rCBV&MTT color map demonstrates high
perfusion rate denoted by areas of red color and some prolongation of MTT within tumor denoted by blue color as well peritumoral region. (D) Signal intensity curve
demonstrates a more initial signal drop indicating higher rCBV with slower return to baseline (rCBV = 8.9). (E) Spectrum (TE = 35 ms) from tumoral region showing marked
Cho elevation with respect to creatine (Cr) and N-acetylaspartate (NAA) which corresponds to areas of high rCBV. (F) Also there is increased perfusion around periphery of the
lesion with high rCBV (5.9) with areas of decreased perfusion within lesion denote necrosis, showing marked elevated lipid peak at spectrum.
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(Table 2).
The peri-tumoral Cerebral blood volume was highly significant
(P = 0.000) in differentiating G4 from G3 with cutoff value of 4.5
and a sensitivity of 85.7%, specificity of 63.2%, PVP of 72% and
NPV of 80% (Table 2).
Regarding MRS study, CHo/Cr was significant in differentiating
G3 from grade-4 glioma (P = 0.02), while CHo/NAA, NAA/Cr and
MI/Cr were not significant (Table 2).4. Discussion
One of the most dilemmas faced by radiologist is to implement
the diagnosis of the CNS glioma and subsequently differentiation
between different grades. Conventional MRI and Diffusion
weighted MRI play a critical role in the diagnosis and now DWI
considered a routine sequence in brain tumor protocol, but still
we need more functional imaging increased capability of MRI as
a satisfactory tool for differentiating the gliomas grades. This study
Fig. 2 (continued)
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HGGs by evaluating specific parameters that show great values
approaching.
In our study we use DCE-MRI parameters as rCBV and MTT. All
were highly significant in differentiation between grade III and
grade IV gliomas, particularly rCBV, in which we use both paramet-ric value and color map which correlate with findings of Zikou et al.
[8], who stated that high grade gliomas have a significant higher
rCBV ratio.
In MTT data analysis, we use color map which shows great
value as excluding HGGs. From this point of view, this study
focused on using this method of DCE-MRI parameters in comparing
Fig. 3. 59-year-old male patient with histologically confirmed grade-III anaplastic oligodendroglioma. (A) Axial T1-weighted post Gd-DTPA image demonstrates lesion at left
hippocampal region with low signal and minimal enhancement. (B) Axial FLAIR images demonstrate increase in T2 signal within lesion without surrounding edema.
(C) Gradient-echo axial DSC MRI with rCBV & MTT color map demonstrates high perfusion rate (yellow color) with mild prolongation of MTT (white yellow color) within
tumor.(D) Signal intensity curve demonstrates a substantial initial signal drop indicating higher rCBV with slower return to baseline (rCBV = 6.2). (E) Spectrum (TE = 35 ms)
from tumoral region showing marked Cho elevation with respect to creatine (Cr) and N-acetylaspartate (NAA) which corresponds to areas of high rCBV.
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deal with one or two parameters only using parametric method. In
our study, we added mean transit time (MTT) as a specific exclud-
ing parameter for glioma, in which we found shortness of MTT in
all cases whatever their grade. This correlated with results of
Law et al. [9] who stated that glioma, particularly high grade glio-
mas will demonstrate elevated rCBV and CBF with decreased MTT.
In this study, we highlight the role of MTT map at expense of
parametric value and to our knowledge, this is the first paper con-
cerning this variant in differentiation of gliomas, so we can apply
this parameter as excluding parameter for gliomas and we shareothers as Law et al. [9] and Pivawer et al. [10] studying MTT value
not map in the evaluation of glioma.
In our study rCBV was the only variable used in glioma grading
in which it was able to differentiate between grade-III and grade-IV
glioma with value of 6 in tumor core with sensitivity and speci-
ficity 90.5% and 68.4% respectively.
These results were compatible with results of Sugahorat et al.
[11] and Shin et al. [12] mentioned that one study of 30 patients
was able to differentiate between grade III and IV glioma with rCBV
value of 7.32, 5.84 and 1.26 for glioblastoma, anaplastic astrocy-
toma and low grade glioma respectively, also with Law [13], who
Fig. 3 (continued)
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rCBV value of 2.14 and HGGs to have rCBV values of 5.18. And also
with Geneidi et al. [14] who stated that perfusion imaging is valu-
able in grading of cerebral gliomas by using rCBV and we consid-
ered that rCBV followed by Cho/Cr ratio are the most specific
parameters for differentiating grade III and grade IV with sensitiv-
ity of 90.5% and specificity 68.4% which correlates with results of
Caulo et al. [15] who stated that the data-driven predictive model
included in order of weight, the following parameters, rCBV in con-
trast enhanced regions, rCBV on areas of lowest signal intensity on
T2-weighted image, age, rCBV of restricted diffusivity region and
Cho/Cr in areas of lowest signal intensity on T2-weighted images,
and they found that the sensitivity and specificity of glioma grad-
ing indexed were better than that of each individual MR image
parameter.
In the evaluation of MRS parameters, we found that Cho/Cr ratio
was most significant in differentiation of HGGs with value of
2.47 ± 0.55 and 2.84 ± 0.45 for grade III and IV respectively, and
however this result did not mention in most previous literature,
but appeared more accurate than Cho/NAA index which mentioned
by other as Caulo et al. [15] and McKnight et al. [16] that demon-
strate 90% sensitivity and 86% specificity by using a Cho/NAA index
(CNI) of 2.5 in distinguishing tumoral tissue from non tumoral tis-
sue and Nelson et al. [17] who stated that the median CNI value for
grade II/IV, grade III/IV and grade IV/IV glioma are 6.9, 7.1 and 9.3
respectively, in which they disagree with our results about CNI for
grade III and IV that was 3.47 ± 0.86 and 3.3 ± 1.0 that was non-
significant in differentiation and explanation of this discrepancy
is mentioned by Nelson who stated that there is some overlap in
CNI between tumors of different grades which may be related to
the variability, clinically it is not uncommon to find some LGGs
with very high Cho/Cr and Cho/NAA ratio and conversely to find
HGGs with lower Cho/Cr and Cho/NAA ratio due to primarily
extensive necrosis which increase false in using metabolite ratios
rather than absolute quantification to compare gliomas grades.
We agree with Law et al. [5], who demonstrated threshold value
of 1.56 for Cho/Cr to provide sensitivity, specificity and positive
and negative predictive values of 75.8%, 47.5%, 81.2% and 39.6%
respectively for determination of HGG versus LGG as we found in
our study but the results of Cho/CR ratio was higher than Law
and this may attributed to the fact that the more high grade, the
more high values of ratio.This also correlates with Law [5] and Orska and Barker [18] who
stated that MRSI usually demonstrates a markedly elevated Cho
with respect to Cr and NAA within tumors and peri-tumoral area
indicates a high grade glioma with tumor infiltrate to surrounding
tissue.
From this point of view we should depend mainly upon DCE-
MRI parameters and MRS parameters as a complementary and
adjuvant tool to avoid such technically obstacles of MRS. As com-
bination of two techniques will increase sensitivity, specificity
and accuracy for differentiation of HGGs and by increasing confi-
dence of such examination, we can avoid unnecessary biopsy, par-
ticularly up to date, histopathological grading is controversy
according to Daumos-Duport [2].
And for these reasons we considered Ch/Cr ratio was the most
significant parameter, among MRSI parameters in differentiation
between grade III and grade IV gliomas.
In general our results are in accordance with a review of the lit-
erature that demonstrates maximal values obtained from Cho/Cr
and Cho/NAA ratios and minimal values for NAA/Cr ratio to be of
utility in differentiation between LGGs and HGGs [19] but there
is little difference that is attributed to our high threshold value
for these parameters due to our planning in differentiating HGGs
only.
In our study we demonstrate elevated lipid and lactate
peaks in grade IV gliomas more than grade III in addition to high
Cho/Cr ratio in surrounding areas of tumor in which we can use
in the differentiation of type III and type IV on the basis of these
parameters and our results are compatible with Li et al. [20] who
stated that lipid and lactate elevation correlate with necrosis in
HGGs.
However, differentiation between LGGs and HGGs is beyond the
scope of this article, but there are some parameters we can use in
algorithm way for differentiation of HGGs by exclusion LGGs as
first step, of these parameters MTT as mentioned above and also
myo-inositol, in which MI/Cr ratio was non-significant in differen-
tiation of HGGs in our study, but the reduction of ratio below 1 is
considered valuable parameter in excluding HGGs, and these find-
ings are compatible with Castillo et al. [21] who stated that myo-
inositol can also be used to differentiate LGGs and HGGs. LGGs
express higher levels of myo-inositol compared with HGGs, due
to the lack of activation of phosphatidylinositol metabolism result-
ing in accumulation of myo-inositol in LGGs.
One of the most interesting results in our study is the study of
surrounding parenchyma, in which we found remarkable changes
of surroundings perfusion and spectroscopic parameter values that
are similar to tumor core area in which we focus on peri-tumoral
region which shows high significant changes with regard to rCBV
in differentiating HGGs and this correlates with the findings of
Cho et al. [22] who stated that the peri-tumoral region can help dif-
ferentiate between infiltrating edema around a primary glioma and
pure vasogenic edema around metastasis and some infiltrating
lesions. But we go more than these results by trying to get rCBV
cutoff value for differentiating grade III and grade IV glioma which
is 4.5 with sensitivity and specificity of 85.7 and 63.2 in which we
think, it is not mentioned as parametric value in previous literature
and we agree with Young [7] who stated that evaluation of the per-
itumoral rCBV can be used to help differentiate a primary glial
tumor from a metastasis Glial tumor that is infiltrative neoplasm
and there are tumor cells in the surrounding T2 signal hyperinten-
sity which will demonstrate elevated rCBV, where metastases are
non-infiltrative and surrounding T2 signal hyperintensity is edema,
showing a non-elevated rCBV, CBF and a prolonged MTT [5].
Also, there is increased Cho/Cr peak in peri-tumoral area in our
study that found in HGGs, particularly grade V that coincides with
results of Lup et al. [23].
Fig. 4. 53-year-old female patient with histologically confirmed grade-IV glioblastoma. (A) Axial T1-weighted post Gd-DTPA image demonstrates lesion at left frontal region
with low signal, non-enhanced anterior portion and heterogeneous enhancement of posterior portion. (B) Axial FLAIR images demonstrate increase in T2 signal within lesion
with surrounding edema and shift to right side and effacement of ventricular system. (C) Gradient-echo axial DSC MRI with rCBV & MTT color map demonstrates high
perfusion rate (red color) with prolongation of MTT (blue color) within tumor. (D) Signal intensity curve demonstrates initial signal drop indicating higher rCBV with slower
return to baseline (rCBV = 6.6) of posterior perfused portion. (E) Spectrum (TE = 35 ms) from tumoral region showing marked Cho elevation with respect to creatine (Cr) and
N-acetylaspartate (NAA) which corresponds to areas of high rCBV and high lipid/lactate peaks at anterior non perfused portion denotes necrosis.
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tumoral area will increase utility and confidence of these parame-
ters in grading of gliomas.
Among the MRS and DCE-MRI parameters, the rCBV was the
most important variance and we can depend on the differentia-
tion of HGGs with measurable cutoff value, and is compatible
with Caula et al. [24] who stated that, we compared grade-III
and grade-IV gliomas to determine whether it is possible to dif-
ferentiate, within the group of high-grade tumors, those with a
poorer prognosis; we found a significant difference in rCBV in
contrast-enhanced areas, and this is in accordance with thereports that vascular endothelial growth factor and other angio-
genic cytokines tend to increase with increasing tumor grade
[23].
Generally, we found that rCBV and Cho/Cr ratio levels were very
sensitive in differentiating LGGs and HGGs, being more at HGGs, in
addition to reduced MTT and these results agree with the results of
Law et al. [5] who stated that high-grade gliomas generally have
higher rCBV measurement and Cho level than low-grade glioma,
and other perfusion parameters, besides rCBV, can also help
increase our specificity such as finding increased MTT (mean tran-
sit time) with region of ischemia.
Fig. 4 (continued)
Table 2
Validity of MRS and contrast-enhanced dynamic MRI study in differentiating grade III
from grade IV according to the WHO classification.
G3 (N = 19)
47.5%
G4 (N = 21)
52.5%
t P
CHo/NAA 3.47 ± 0.86 3.3 ± 1.0 0.58 0.56 NS
CHo/Cr 2.47 ± 0.55 2.84 ± 0.45 2.31 0.02*
NAA/Cr 0.84 ± 0.15 0.86 ± 0.26 0.29 0.77 NS
MI/Cr 0.79 ± 0.08 0.82 ± 0.08 1.32 0.19 NS
Tumor core relative
cerebral blood
volume (rCBV)
5.37 ± 1.28 7.85 ± 0.93 7.03 0.000**
Peritumoral cerebral
blood volume(rCBV
4.12 ± 1.34 6.13 ± 1.69 4.12 0.000**
Normal brain tissue 2.5 ± 1.14 4.64 ± 0.94 6.48 0.000**
NS = non-significant.
* Significant.
** Highly significant.
Table 1
MRI technique.
Sequence FLAIR T1 FSE T2 SE
– TR (ms) 10,000 600 3000
– TE (ms) 125 14 100
– Slice thickness (mm) 4–5 4–5 4–5
– Gap (mm) 1 1 1
– FOV (cm) 24  24 24  24 24  24
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